90 completed, 6 unknown, 3 recruiting, 2 active not recruiting. 105 Phase 1, 27 Phase 2.
Follow Acneiform Eruptions: new trials by email Literature Review of Acneiform Eruptions trials Research Report on Acneiform Eruptions
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative Effectiveness of Clindamycin-Retinoid, Clindamycin-Retinoid-Dexamethasone, and 10% SM-hUCMSC Secretome Gel in the Improvement of Mild-to-Moderate Acne Vulgaris Mediklin TR, Solanum Night Cream, Gel Sekretome SM-hUCMSC 10% - Acne Vulgaris | Phase 1 / Phase 2 | Not yet recruiting | Yohanes Firmansyah, dr, MH, MM | 189 | 2026-04-18 | 2026-04-01 |
| A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris. HB0043, Placebo - Acne Vulgaris | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Huaota Biopharmaceutical Co., Ltd. | 21 | 2026-03-27 | 2026-03-04 |
| Evaluating Microneedling With CBD and Hempseed Oil for Acne Vulgaris Safety and Efficacy Microneedling with CBD - Acne Vulgaris (Disorder) | Phase 1 | Unknown | Rejuva Medical Aesthetics | 20 | 2025-12-01 | 2024-08-23 |
| A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris Tretinoin Gel Microsphere, 0.04%, RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.04%, Placebo Control - Acne Vulgaris | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 1043 | 2025-08-04 | 2026-03-13 |
| Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne Acne mRNA vaccine, Placebo - Acne | Phase 1 / Phase 2 | Recruiting | Sanofi Pasteur, a Sanofi Company | 228 | 2025-07-03 | 2026-07-09 |
| Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne TVB-3567, Placebo - Acne | Phase 1 | Recruiting | Sagimet Biosciences Inc. | 152 | 2025-06-03 | 2026-10-21 |
| Efficacy, Safety Profile, and Post-Acne Sequelae of 0.025% Retinoic Acid Cream vs. 0.1% Adapalene Cream in Mild Acne Vulgaris in Fitzpatrick Skin Types III-V retinoic acid cream 0.025%, adapalene cream 0.1% - Acne Vulgaris | Phase 1 / Phase 2 | Completed | Universitas Indonesia | 23 | 2024-11-30 | 2025-06-11 |
| A Study to Learn About the Study Medicine Called PF-07905428 in Healthy Participants and Participants With Acne Vulgaris PF-07905428, Placebo - Acne Vulgaris | Phase 1 | Completed | Pfizer | 52 | 2024-11-22 | 2025-12-30 |
| Pharmacokinetics, Safety and Tolerability of Clascoterone Cream 1% in Healthy Chinese Adult Subjects Clascoterone Cream 1% - Acne Vulgaris | Phase 1 | Completed | Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. | 12 | 2024-08-01 | 2025-01-28 |
| Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy Clascoterone 1% Top Cream, Vehicle - Acne Vulgaris | Phase 1 / Phase 2 | Active not recruiting | Stanford University | 18 | 2024-07-22 | 2026-04-30 |
| A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris Trifarotene Cream 0.005%, AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG, AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT - Acne Vulgaris | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 1000 | 2024-06-20 | 2024-12-13 |
| A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris. Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%, CABTREO Topical Gel, Placebo Control - Acne Vulgaris | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 382 | 2024-05-13 | 2024-11-05 |
| Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne Acne mRNA vaccine, Placebo - Acne | Phase 1 / Phase 2 | Recruiting | Sanofi Pasteur, a Sanofi Company | 800 | 2024-04-05 | 2026-08-21 |
| Toxicity and Efficacy Evaluation of Topical Minoxidil in Acne Vulgaris topical minoxidil in Acne Vulgaris - Acne Vulgaris | Phase 1 / Phase 2 | Unknown | Chang Gung Memorial Hospital | 26 | 2023-07-11 | 2023-11-03 |
| A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris Trifarotene Cream 0.005%, Placebo, AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories) - Acne Vulgaris | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 762 | 2023-02-22 | 2023-10-02 |
| Effectivity and Safety of Combination Cream of Salicylic Acid, Aqua Posae Filiformis, Niacinamide, Lipohydroxy Acid, Procerad and Zinc PCA Combination Cream, Adapalene 0,1% cream - Acne Vulgaris | Phase 1 | Unknown | Dr.dr.Irma Bernadette, SpKK (K) | 284 | 2022-08-01 | 2023-04-06 |
| Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029 GT20029 Gel, GT20029 Gel Placebo - Androgenetic Alopecia, Acne Vulgaris | Phase 1 | Completed | Suzhou Kintor Pharmaceutical Inc, | 123 | 2022-02-10 | 2023-08-14 |
| Effectivity and Safety of Combination of Spent Grain Wax, Argan Oil, Shea Butter and Saccharide Isomerate Combination cream, Placebo cream - Acne Vulgaris | Phase 1 | Unknown | Dr.dr.Irma Bernadette, SpKK (K) | 20 | 2021-12-20 | 2022-01-11 |
| Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris ORG101 - Experimental 1, ORG101PL - Placebo 1 - Acne Vulgaris, Acne | Phase 1 | Completed | Sanofi Pasteur, a Sanofi Company | 38 | 2021-09-28 | 2024-01-24 |
| To Evaluate the Safety, Tolerability and PK of GT20029 Gel and Solution in Healthy Subjects GT20029, GT20029 matching placebo - Acne, Alopecia | Phase 1 | Completed | Suzhou Kintor Pharmaceutical Inc, | 92 | 2021-07-25 | 2024-10-23 |
Showing 20 of 105. Sign in to see all of them.
Acne Vulgaris (104) · Cicatrix (3) · Alopecia (2) · Cellulitis (2) · Rosacea (2) · Acne Keloid (1) · Bulbo-Spinal Atrophy, X-Linked (1) · Dermatitis, Phototoxic (1) · Erythema (1) · Flushing (1) · Granuloma Annulare (1) · Hyperpigmentation (1) · Hypertrichosis (1) · Keloid (1) · Lymphoma, Follicular (1)
Skin Diseases (105) · Skin and Connective Tissue Diseases (105) · Sebaceous Gland Diseases (103) · Pathological Conditions, Signs and Symptoms (9) · Pathologic Processes (5) · Hair Diseases (4) · Connective Tissue Diseases (3) · Fibrosis (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Hypotrichosis (2) · Infections (2) · Inflammation (2) · Neoplasms (2) · Neoplasms by Histologic Type (2)
Gels (10) · berdazimer sodium (8) · Clindamycin (7) · Adapalene (6) · Dapsone (5) · clindamycin phosphate (4) · tazarotene (4) · Benzoyl Peroxide (3) · Doxycycline (3) · Isotretinoin (3) · Minocycline (3) · Lidocaine, Prilocaine Drug Combination (2) · Tretinoin (2) · trifarotene (2) · Adapalene, Benzoyl Peroxide Drug Combination (1)
Sun Pharmaceutical Industries, Inc. (16) · GlaxoSmithKline (8) · Novan, Inc. (8) · Stiefel, a GSK Company (7) · Allergan (4) · Bausch Health Americas, Inc. (4) · Dermira, Inc. (3) · Miglani, Anjali (3) · Sanofi Pasteur, a Sanofi Company (3) · University of California, Irvine (3) · Dr.dr.Irma Bernadette, SpKK (K) (2) · Naked Biome, Inc. (2) · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (2) · Suzhou Kintor Pharmaceutical Inc, (2) · Universitas Indonesia (2)
United States (50) · Canada (7) · China (6) · Indonesia (5) · Australia (4) · Israel (4) · India (3) · Japan (3) · Mexico (2) · Belize (1) · Dominican Republic (1) · Egypt (1) · France (1) · Germany (1) · Iran (1)
Natalie Yantovskiy (5) · Anya Loncaric (4) · Anjali Miglani, BHMS (3) · Emma Taylor, MD (2) · Irma BS Sitohang, MD (2) · Joyce Rico, MD (2) · Annabelle Matias, MD (1) · Anne Lynn S Chang, MD (1) · Arie Ingber, MD, Prof (1) · Arie Kusumawardani (1) · Avner Shemer, MD (1) · Brian D Zelickson, MD (1)
PMID 18394082, PMID 21108671, PMID 21572783, PMID 22859988, PMID 23337890, PMID 23631911, PMID 24931753, PMID 27272073, PMID 27303708, PMID 33548303, PMID 34804358
2025 (2)